Previous 10 | Next 10 |
BERKELEY HEIGHTS, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that management will be...
Image source: The Motley Fool. CorMedix Inc Common Stock (NASDAQ: CRMD) Q1 2022 Earnings Call May 12, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: CorMedix Inc Common Stock (CRMD) Q1 2022 Earnings Call Transcript...
CorMedix Inc. (CRMD) Q1 2022 Earnings Conference Call May 12, 2022 16:30 ET Company Participants Daniel Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Erin Mistry - Senior Vice President and Head, Payer Strate...
CorMedix press release (NASDAQ:CRMD): Q1 GAAP EPS of -$0.18 beats by $0.04. Revenue of $0.01M (-88.9% Y/Y) misses by $0.01M. Joe Todisco, CorMedix CEO, commented, “We are very pleased to share the updates this week regarding the business and plans for commercialization. If approved by ...
BERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for th...
CorMedix (NASDAQ:CRMD) hired Joe Todisco as its new CEO, effective May 10. The infectious and inflammatory diseases developer also said that Chief Commercial Officer Tom Nusbickel has left. Donna Ucci joined the Company as SVP and head of global quality. Liz Hurlburt, EVP ...
BERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced updates regarding its le...
AAIC, ACB, ACHV, AFRM, AGRO, AGRX, APDN, APTX, AQN, AVPT, AXU, BANX, BBI, BEAT, BIOL, BLBD, BLND, BOXL, BSQR, CBAY, CDXC, CLLS, CLVR, CODX, COMP, CORZ, CRMD, CTIC, CURI, CWCO, DARE, DUOL, EDR, ETON, EYEN, FIGS, GPL, GWH, HLI, HTGM, IBIO, IDN, OTCQB:IGXT, IMMR, INDI, INTZ, INUV, JOBY, KMPH, LC...
BERKELEY HEIGHTS, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its...
BERKELEY HEIGHTS, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the formation of a new...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has...